No Data
No Data
Tianjin Tianyao Pharmaceuticals (600488.SH): The revenue from products sold to the USA accounts for a small proportion of the total revenue.
Gelonghui reported on April 11 that Tianjin Tianyao Pharmaceuticals (600488.SH) stated on the interaction platform that the company's products are exported to over 70 countries and regions globally, with the revenue from products sold in the USA accounting for a small portion of total revenue. The company will also actively expand its overseas business in non-USA regions, continue to increase investment in technological research and development, strengthen overseas product registration, develop new markets, enhance the company's global competitiveness, and fully protect the interests of the company and all Shareholders.
Jinyao Pharmaceutical: Summary of the 2024 Annual Report of Jinyao Pharmaceutical Co., Ltd.
Jinyao Pharmaceutical: 2024 Annual Report of Jinyao Pharmaceutical Co., Ltd.
2024 Annual Report of Tianjin Pharmaceutical Co., Ltd.
Summary of the 2024 Annual Report of Tianjin Pharmaceutical Co., Ltd.
Tianjin Tianyao Pharmaceuticals (600488.SH): In 2024, net income is expected to grow by 14.01% year-on-year, proposing a dividend of 0.98 yuan per 10 shares.
Gelonghui March 26 announcement | Tianjin Tianyao Pharmaceuticals (600488.SH) announced the 2024 annual report, in which the company achieved revenue of 3.215 billion yuan, a decrease of 15.00% year-on-year, net income attributable to shareholders of the listed company was 0.133 billion yuan, an increase of 14.01%, and export revenue reached 0.145 billion dollars. A cash dividend of 0.98 yuan is distributed for every 10 shares to all shareholders.